Although this research area is the most promising avenue for long COVID -- wrt biologic rationale -- the major anti-viral trials for long COVID were negative.
STOP-PASC trial [2] and PAXLC [3] were both 15-day courses of Paxlovid and showed no benefit across patient reported outcomes.
The real question however, is whether anti-virals have benefit in patients with active viral replication. Like only cases of long COVID can be implicated to viral persistence.
STOP-PASC did collect stool PCR at baseline, but every tested sample was negative. PAX LC later reported a exploratory biomarker analysis of 82 PAX LC participants did measure circulating SARS-CoV-2 S1 and full-length Spike, and wasn't powered to find a difference. Notably, spike presence doesn't necessarily mean active viral replication [4].
As an aside, mchusma's post is probably right. Viral disease is not being associated with more and more long term diseases. EBV is being linked to MS, cervical cancer to HPV, and so on.
[1] https://www.sciencedirect.com/science/article/pii/S147330992... [2] https://jamanetwork.com/journals/jamainternalmedicine/fullar... [3] https://pubmed.ncbi.nlm.nih.gov/40188838 [4] www.medrxiv.org/content/10.64898/2026.02.24.26347001v1.full
A deceased person is also a decedent. Adjective vs noun. Cool.